Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Lobe Sciences Ltd. (LOBE) files a patent application for the preparation and use of its proprietary and stable psilocin related compounds
  • The company focuses on discovering and developing psychedelic derived medicines for neurologic and brain disease
  • Lobe Sciences (LOBE) is a life sciences company focused on psychedelic medicines
  • Lobe Sciences (LOBE) is up by 20 per cent, trading at C$0.06 per share at 4 pm ET

Lobe Sciences (LOBE) has filed a patent application for the preparation and use of its proprietary and stable psilocin related compounds.

The application covers the preparation of stable psilocin prodrugs and analogues, further strengthening the intellectual property portfolio of the company.

The Canadian biopharmaceutical company is committed to discovering and developing psychedelic-derived medicines for neurologic and brain diseases.

The CEO of Lobe Sciences, Philip Young commented on the news.

“Our patent portfolio now consists of multiple patent filings for the use and delivery of psilocybin, psilocin analogues and N-Acetyl Cysteine (NAC), as well as a new patent that covers the uses and preparation of multiple proprietary, stable forms of the psilocin molecule. The company is actively pursuing drug development programs using two initial proprietary psilocin analogues. L-130 targeting neurologic conditions such as severe anxiety, Post Traumatic Stress Disorder (PTSD), as well as other brain traumas. L-131, a second new chemical entity related to psilocin and covered in the recently filed patent application, is a drug candidate for a second neurological disorder affecting children.”

Lobe is dedicated to delivering a patient friendly treatment plan that focuses on offering therapeutics in patients’ homes, physician’s offices or in the emergency department in a local hospital setting. Delivering a non-hallucinatory dose of our proprietary compounds, over several days should enable patients and their personal doctors the opportunity to maintain their normal routine while receiving treatment, allowing significantly more people access to this new therapeutic approach.

Lobe Sciences (LOBE) is a life sciences company focused on psychedelic medicines.

Lobe Sciences (LOBE) is up by 20 per cent, trading at C$0.06 per share at 4 pm ET.

More From The Market Herald

" Lobe Sciences (CSE: LOBE) update psilocin compounds and development plans on site

Lobe Sciences (LOBE) is updating its corporate presentation describing plans for advancing the development of its psilocin analogues L-130 and L-131.
PharmaDrug - CEO, Daniel Cohen

" PharmaDrug (CSE:PHRX) completes milestone to support cGMP production of PD-001

PharmaDrug (PHRX) has laid the groundwork to support cGMP production of cepharanthine-2HCL for use in the drug product production of PD-001.
Small Pharma - CEO, George Tziras.

" Small Pharma (TSXV:DMT) announces NCIB

Small Pharma (DMT) has received TSXV approval for a normal course issuer bid.